More than just the median: Calculating survival times for patients with HER2 positive, metastatic breast cancer using data from recent randomised trials

Surprisingly little is known of survival beyond the median for HER2-positive MBC. Longer trial follow-up is required to help clinicians estimate and explain the best-case scenario. Simple multiples of the median OS provide a reasonable framework for estimating then explaining survival times to patients.